What does retatrutide research tell you so far?

What do the numbered study phases mean?

Retatrutide hasn't been approved. Eli Lilly made it to copy three hormones. One affects hunger. That hormone is called GLP-1, and it also helps insulin handle blood sugar. The third may raise energy use and cut liver fat. Phase 1 is the first safety check; that work began in 2019. Phase 2 asks whether a drug seems to work. Those results came out in 2022 and 2023. Phase 3 tests many more people and checks the early findings. In the main Phase 2 obesity study, average weight loss was 24.2 percent over 48 weeks ^[1]. You'll hear that number often. Those missing Phase 3 findings mean you can't know what you'll lose or how your body will react.

What did the first small safety tests find?

The first test found that blood held about half as much drug after six days. That slow clearing is why researchers tried a weekly shot ^[11]. The next small test followed 72 adults with type 2 diabetes. Five groups got rising amounts: 0.5, 1.5, 3, 3/6, or 3/6/9/12 mg. Each week, doctors put the shot under the skin for 12 weeks ^[4]. The highest-amount group lost 8.96 kilograms beyond the loss with placebo after 12 weeks. The 6.75 to 11.16 kilogram range shows the doubt around that best estimate; the study called it 90% confidence. At 3 mg, blood sugar fell 2.8 millimoles per liter, a lab unit. That means sugar went down, not that the same drop would be safe for you ^[4]. Side effects hit 63 percent, mostly in the gut. The result was safe enough for Phase 2 to begin. You'd still need your doctor to compare it with your health.

How much weight did people lose in Phase 2?

In Phase 2, the obesity study followed 338 adults. Their weight was high for their height: a score of 30 or more, or 27 plus another health problem. By chance, they got 1, 4, 8, or 12 mg each week, or a placebo containing no retatrutide. The shots went beneath the skin for 48 weeks ^[1].

By week 48, average loss reached 24.2 percent in the 12 mg group. The placebo group lost 2.1 percent ^[1]. That's a large gap in one early study. Nausea and vomiting were common, as were diarrhea and constipation. Side effects made 18 percent quit at the top amount. Resting pulse rose about 5–7 beats a minute and peaked near 24 weeks. Grave low blood sugar didn't occur.

A large average still can't tell you what your body would bear for many weeks. In 2025, a review of Phase 1/2 work called loss of up to 24 percent a big gain over older drugs. The writers thought the third hormone job might help explain it ^[6]. Your loss could be far smaller.

What changed in Phase 2 for type 2 diabetes?

In a 36-week Phase 2 study, 281 adults had type 2 diabetes. Food and exercise hadn't lowered their blood sugar enough. By chance, they got 0.5–12 mg of retatrutide, a placebo, or another drug ^[2].

At 12 mg, the blood test that shows about three months of blood sugar fell 2.02 percent by 24 weeks. The placebo group had a 0.01 percent fall. By 36 weeks, body weight fell 16.94 percent with retatrutide and 3.00 percent with placebo ^[2]. In Phase 2, mild or fair stomach trouble affected 35 percent. There were no deaths. Grave low blood sugar didn't occur.

In 2026, a Phase 3 study found lower blood sugar and weight when retatrutide was used alone. Most side effects were mild or fair gut trouble. Grave low blood sugar didn't occur ^[12]. Your doctor would still need to read your own blood tests.

How much did liver fat fall in the study?

This Phase 2 study followed 98 people whose weight was high for their height. Each had fatty liver, with at least 10 percent liver fat measured by a special scan ^[5].

After 24 weeks, liver fat fell 42.9 percent with 1 mg. It fell 57.0 percent with 4 mg, 81.4 percent with 8 mg, and 82.4 percent with 12 mg. The placebo group had a 0.3 percent rise ^[5]. At 12 mg, 86 percent reached a normal liver-fat level below 5 percent by week 24. The drop was still 86.0 percent at week 48 ^[5]. No one in this group had type 2 diabetes. A blood-sugar change can't explain all of that liver result. You'd need your doctor to say what a scan means for you.

What did the close-up lab pictures add?

In 2024, scientists took close-up pictures of retatrutide attached at three cell spots used by hormones ^[3]. The hunger-and-sugar hormone is called GLP-1. The pictures showed one drug reaching its spot and two others ^[3]. GLP-1 wasn't the strongest match in the lab. The fit was strongest at the spot used by the hormone that helps insulin after food ^[3]. The useful point isn't a lab code. Retatrutide copies three hormone jobs, not one.

A 2026 review left one key question open. Glucagon is the third hormone; it makes the liver release sugar and may raise energy use. Researchers don't know if that part helps weight stay off for years ^[13]. Only long studies can answer it. You don't yet have that answer for your future.

What must the Phase 3 studies still answer?

Four large Phase 3 studies are under way. TRIUMPH-1 checks weight loss and safety in people with obesity ^[7]. TRIUMPH-3 includes people with heart disease ^[8]. A third tracks heart rhythm, heart attacks, strokes, and kidney health ^[9]. The fourth compares retatrutide with tirzepatide, a drug that copies the hunger hormone called GLP-1 and one other hormone job ^[10]. None had reported its main result by mid-2026.

In 2024, a medical article called retatrutide the first three-hormone drug made for obesity. It said Phase 3 must provide the firm answer ^[14].

Another 2024 review raised two plain concerns. The GLP-1 effect slows the stomach, which may matter during anesthesia. The three hormone effects may also cause harm that short studies missed ^[15]. Until the large studies report, you won't know the balance for your health.